Belgium· BE-AMP-SAM447093-00
Tybost 150 mg
A cobicistat product containing cobicistat, registered in Belgium by Gilead Sciences Ireland UC. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Cobicistat is registered in 9 of 19 countries.
Countries holding a registration under ATC V03AX03 (cobicistat), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Cobicistat · ATC V03AX03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Cobicistat
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Belgium (BE)
- ATC code
- V03AX03
- ATC class
- Cobicistat
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
541 interactions on record for cobicistat.
Graded by severity as the source publishes them — 243 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cobicistat · interactions on record
541 records
- 243 severe
- 277 moderate
- 21 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- LoperamideA07DA03severe
- EluxadolineA07DA06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cobicistat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTYBOSTGilead Sciences Ireland UC, Carrigtohill
- SpainTYBOST 150mg comprimidos recubiertos con peliculaGilead Sciences Ireland Unlimited Company
- FinlandTybostGilead Sciences Ireland UC
- IrelandTybost 150 mg film-coated tabletsGilead Sciences Ireland UC
- NetherlandsTybost 150 mg filmomhulde tablettenGilead Sciences Ireland UC
- PolandTybostGilead Sciences Ireland UC
- SwedenTybost 150 mg Filmdragerad tablettGilead Sciences Ireland UC
- United StatesTybostGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tybost
- Liechtenstein · Tybost
- Norway · Tybost
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbe55d93-5946-4bb1-972c-82c0904a93ce GET /v1/drugs/dbe55d93-5946-4bb1-972c-82c0904a93ce?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "REVOKED",
"name_en": "Tybost 150 mg",
"name_fr": "Tybost 150 mg",
"name_nl": "Tybost 150 mg",
"amp_code": "SAM447093-00",
"strengths": [
"150.0000",
"150.0000"
],
"pack_count": 2,
"substances": [
"Cobicistat",
"E 110"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Cobicistat",
"authorisation_numbers": [
"EU/1/13/872/001",
"EU/1/13/872/002"
]
}See everything about cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.